Drug Approval | January 05, 2026
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Consolidated revenue from operations stood at Rs. 111.05 crore
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated
